A light-emitting device includes a first electrode, a second electrode facing the first electrode, and an interlayer including an emission layer between the first electrode and the second electrode and an electron transport region between the emission layer and the second electrode. The electron transport region includes an electron transport layer and an electron injection layer between the electron transport layer and the second electrode. The electron transport layer includes a first material and a second material, the electron injection layer includes a third material and a fourth material, and an amount of the third material is in a range of about 50 parts by weight to about 99 parts by weight, based on a total of 100 parts by weight of the electron injection layer. The first material to the fourth material are respectively the same as described in the specification.

Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

##STR00001##

An organic compound, an electroluminescent material and its application are provided in the present disclosure. The organic compound includes a structure: ##STR00001## X is selected from O, S, N—R.sub.N1, and CR.sub.C1R.sub.C2; Y is selected from O, S, N—R.sub.N2, CR.sub.C3R.sub.C4, O═S═O, SiR.sub.S1R.sub.S2, O═P—Ar.sub.1, and S═P—Ar.sub.2, R.sub.N1, R.sub.N2, R.sub.C1, R.sub.C2, R.sub.C3, R.sub.C4, R.sub.S1, and R.sub.S2 are each independently selected from C1˜C20 linear or branched alkyl, C6˜C40 aryl, and C3˜C40 heteroaryl; Ar.sub.1 and Ar.sub.2 are each independently selected from C6˜C40 aryl and C3˜C40 heteroaryl; L.sub.1, L.sub.2, L.sub.3, L.sub.4, and L.sub.5 are each independently selected from a single bond, C6˜C40 arylene, and C3˜C40 heteroarylene; R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are each independently selected from deuterium, C1˜C20 linear or branched alkyl, C1˜C20 alkoxy, C1˜C20 alkylthio, C3˜C20 cycloalkyl, C6˜C40 aryl, C3˜C40 heteroaryl, and C6˜C40 arylamino; and n.sub.1, n.sub.2, n.sub.3, n.sub.4, n.sub.5, m.sub.1, m.sub.2, m.sub.3, m.sub.4, and m.sub.5 are integers each independently selected from 0-2.

Provided is an organic electroluminescent element having high efficiency, a long lifetime, and bending resistance. An organic electroluminescent element includes a light emitting layer and an electron transport layer adjacent to the light emitting layer between a positive electrode and a negative electrode. A host compound of the light emitting layer has an ionization potential deeper than that of a light emitting dopant of the light emitting layer by 0.3 eV or more. At least one organic compound contained in the electron transport layer has a molecular dipole moment of 6.0 debye or more.

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. ##STR00001##

This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

##STR00001##

The invention concerns new types of porous coordination polymers (MOF) and a method for their preparation. MOFs have been prepared through synthesis of salts of trivalent cations M.sup.3+, the source of which are aluminium, chromium, iron or yttrium salts, it is advantageous if of chlorides, nitrates or sulphates, with linkers carrying two or more phosphinic groups under presence of solvent. Linkers are phenylene-1,4-bis(R phosphinic acid) (PBPA) and biphenylene-4,4′-bis(R phosphinic acid) (BBPA). For the prepared MOFs, the structure has been tested using x-ray powder diffraction, specific surface and porousness which have been characterised through adsorption isotherm of nitrogen and further the stability of prepared MOFs has been determined using thermogravimetric analysis. All the prepared MOFs have been stable around 400° C. and have contained mesopores or micropores where hydrogen or CO.sub.2, for example, can be stored.

Tridentate platinum, palladium, and gold complexes of Formulas A-I and A-II and tridentate iridium and rhodium compounds of Formulas B-I, B-II, and B-III suitable for delayed fluorescent and phosphorescent or phosphorescent emitters in display and lighting applications. ##STR00001##